# US 2003/0203933 A1 · Novel curcumin analogues and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0203933 A1
- Document ID: US20030203933A1
- Status: Published application
- Kind: A1
- Application number: 10/124,642
- Filed: 2002-04-17
- Published: 2003-10-30
- Earliest claimed: 2002-04-17
- Assignees: The University of North Carolina at Chapel Hill
- Inventors: Kuo-Hsiung Lee; Junko Ishida; Hironori Ohtsu; Hui-Kang Wang; Hideji Itokawa; Chawnshang Chang; Charles C-Y. Shih
- Web page: https://patentgrep.com/patent/US20030203933A1

## CPC

- C07C 49/755: a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
- A61P 5/28: Antiandrogens
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 15/16: Masculine contraceptives
- A61P 17/10: Anti-acne agents
- A61P 17/14: for baldness or alopecia
- A61P 25/02: for peripheral neuropathies
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 49/248: having unsaturation outside the aromatic rings
- C07C 49/255: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07C 49/84: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07C 59/84: containing six membered aromatic rings
- C07C 69/738: Esters of keto-carboxylic acids {or aldehydo-carboxylic acids}
- C07C 205/45: the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds capable of acting as androgen receptor antagonists, pharmaceutical formulations containing the same, and methods of use thereof. Such uses include, but are not limited to, use as antitumor agents, particularly for the treatment of cancers such as colon, skin and prostate cancer and to induce androgen receptor antagonist activity in a subject afflicted with an androgen-related affliction. Examples of androgen-related afflictions include, but are not limited to, baldness, hirsutism, behavioral disorders, acne, and uninhibited spermatogenesis wherein inhibition of spermatogenesis is so desired.

## Claims

### Claim 1

A compound according to formula I:
9
wherein:
R1 and R2 are each independently selected from the group consisting of alkoxy, nitro, amino, and dialkylamino;
R3 and R4 are each independently selected from the group consisting of hydroxy, alkoxy, and —OR7C(O)R8, wherein R7 is lower alkylene and R8 is alkoxy;
or R1 and R3 together are alkylenedioxy;
or R2 and R4 together are alkylenedioxy;
R5 and R6 are each independently selected from the group consisting of H, halogen, and nitro;
X1 is N, or X1 is C bonded to a H, alkoxy or nitro; and
X2 is N, or X2 is C bonded to a H, alkoxy or nitro.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein R1 and R2 are each independently selected from the group consisting of alkoxy, nitro, amino, and dimethylamino.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein R1 and R3 together are methylenedioxy or ethylenedioxy.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein R2 and R4 together are methylenedioxy or ethylenedioxy.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein R5 and R6 are each independently selected from the group consisting of H, F, and nitro.

### Claim 6 (depends on 1)

The compound according to claim 1 having the formula:
10

### Claim 7 (depends on 1)

The compound according to claim 1 having the formula:
11

### Claim 8

A compound according to formula II:
12
wherein:
R11 and R12 are each independently selected from the group consisting of alkoxy, nitro, amino, and dialkylamino;
R13 and R14 are each independently selected from the group consisting of hydroxy, alkoxy, and —OR19C(O)R19, wherein R18 is lower alkylene and R19 is alkoxy.
or R11 and R13 together are alkylenedioxy;
or R12 and R14 together are alkylenedioxy;
R15 and R16 are each independently selected from the group consisting of H, halogen, and nitro;
R17 is —R20C(O)OR21, wherein R20 is alkylene and R21 is H or alkyl;
X3 is N, or X3 is C bonded to a H, alkoxy or nitro; and
X4 is N, or X4 is C bonded to a H, alkoxy or nitro.

### Claim 9 (depends on 8)

The compound according to claim 8, wherein R11 and R12 are each independently selected from the group consisting of alkoxy, nitro, amino, and dimethylamino.

### Claim 10 (depends on 8)

The compound according to claim 8, wherein R11 and R13 together are methylenedioxy or ethylenedioxy.

### Claim 11 (depends on 8)

The compound according to claim 8, wherein R12 and R14 together are methylenedioxy or ethylenedioxy.

### Claim 12 (depends on 8)

The compound according to claim 8, wherein R15 and R16 are each independently selected from the group consisting of H, F, and nitro.

### Claim 13 (depends on 8)

The compound according to claim 8 having the formula:
13

### Claim 14 (depends on 8)

The compound according to claim 8 having the formula:
14

### Claim 15

A compound according to formula III:
15
wherein:
R25 and R26 are each independently H or lower alkyl;
R27, R28, R29 and R30 are each alkoxy;
R31 is H or lower alkyl.

### Claim 16 (depends on 15)

The compound according to claim 15 having the formula:
16

### Claim 17 (depends on 1, 8, 15)

A pharmaceutical formulation comprising a compound according to claim 1, 8 or 15 in a pharmaceutically acceptable carrier.

### Claim 18 (depends on 17)

The pharmaceutical formulation according to claim 17, wherein said carrier is an aqueous carrier.

### Claim 19 (depends on 1, 8, 15)

A method of treating a cancer, comprising administering to a subject in need thereof a treatment effective amount of a compound according to claim 1, 8 or 15.

### Claim 20 (depends on 19)

The method according to claim 19, wherein said cancer is selected from the group consisting of skin cancer, small cell lung cancer, testicular cancer, lymphoma, leukemia, esophageal cancer, stomach cancer, colon cancer, breast cancer, endometrial cancer, ovarian cancer, central nervous system cancer, liver cancer and prostate cancer.

### Claim 21 (depends on 20)

The method according to claim 20, wherein said cancer is prostate cancer.

### Claim 22 (depends on 20)

The method according to claim 20, wherein said cancer is colon cancer.

### Claim 23 (depends on 19)

The method according to claim 19, wherein said subject is afflicted with antiandrogen withdrawal syndrome.

### Claim 24 (depends on 1, 8, 15)

A method of inducing androgen receptor antagonist activity, said method comprising contacting a cell with an androgen receptor antagonist effective amount of a compound according to claim 1, 8 or 15.

### Claim 25 (depends on 24)

The method according to claim 24, wherein said cell is a cancer cell.

### Claim 26 (depends on 24)

The method according to claim 24, wherein said contacting step is carried out in vivo.

### Claim 27 (depends on 24)

The method according to claim 24, wherein said contacting step is carried out in vitro.

### Claim 28 (depends on 1, 8, 15)

A method of inducing androgen receptor antagonist activity in a subject afflicted with an androgen-related affliction, said method comprising administering an androgen receptor antagonist effective amount of a compound according to claim 1, 8 or 15.

### Claim 29 (depends on 28)

The method according to claim 28, wherein said subject is afflicted with baldness.

### Claim 30 (depends on 28)

The method according to claim 28, wherein said subject is afflicted with hirsutism.

### Claim 31 (depends on 28)

The method according to claim 28, wherein said subject is afflicted with a behavioral disorder.

### Claim 32 (depends on 28)

The method according to claim 28, wherein said subject is afflicted with acne.

### Claim 32 (depends on 1, 8, 15, 27)

The method according to claim 27, wherein said subject is a male subject and said androgen receptor antagonist effective amount of a compound according to claim 1, 8 or 15 inhibits spermatogenesis.
